Dr. Kim received his M.D. from the University of Washington, was a Howard Hughes Medical Institute-National Institutes of Health Research Scholar under Dr. Stephen I. Katz, and completed his residency in dermatology at the Perelman School of Medicine at the University of Pennsylvania. He completed a postdoctoral fellowship under Dr. David Artis, leading to a Master of Translational Research (MTR). His laboratory focuses on the regulatory mechanisms that underlie skin inflammation and the sensation of itch as a model paradigm of neuroimmunology. Key discoveries include the first identification of group 2 innate lymphoid cells (ILC2s) in the skin of both mice and humans, novel contributions of basophils, ILC2s, and natural killer (NK) cells to skin inflammation, and unveiling how different innate immune cells and type 2 cytokines/JAK signaling directly influence sensory neuronal responses. He has >80 peer-reviewed publications, multiple NIH grants, designed pivotal clinical trials, and is an inventor of multiple itch-centered technologies. His research in neuroimmune regulation of itch and atopic dermatitis has led to awards and funding from the NIH, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, American Society for Clinical Investigation, American Dermatological Association, and International League of Dermatological Societies. He holds a patent for the use of JAK inhibitors for chronic itch. He is on the scientific advisory board for Abrax Japan, Granular Therapeutics, Recens Medical, National Eczema Association, and Cell Reports Medicine. He is section editor for Journal of Immunology and on the board of reviewing editors for eLife.